ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy. ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field. Source
No articles found.
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...
BrainStorm (NASDAQ:BCLI) is a biotechnology com...
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
United-Guardian, Inc. ("United") is a diversified company that conducts research, ...
United-Guardian, Inc. ("United") is a diversifi...
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-stage biotechnology company focused ...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-s...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Advaxis was founded on the vision that no one should suffer from the burdens of ca...
Advaxis was founded on the vision that no one s...
Join the National Investor Network and get the latest information with your interests in mind.